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ABSTRACT
Raspberry ketone (RK) is a natural compound with anti-inflammatory properties that may
benefit tissue healing. Effects of RK on inflammation and healing were evaluated by examining
macrophage polarization in response to guided bone regeneration (GBR) membranes loaded with
0, 100 or 500 μg RK over 4 weeks in a rat calvarial defect model. Initially, pro-inflammatory M1
macrophage phenotypes remove damaged tissues and bacteria and then transition to pro-healing
M2 phenotypes to coordinate tissue repair and formation in wounds. Immunohistochemical
staining was used to characterize M1 and M2 macrophage phenotypes using CD68 as a PAN
macrophage marker, iNOS for M1 and CD206 for M2 phenotype. Results indicated membranes
with 100 μg RK facilitated M1 to M2 transition in comparison to higher 500 μg dose at 2 weeks
post implantation. Greater expression of M2 phenotypes is reported to positively effect
osteogenesis in GBR process. Therefore, RK shows promise for promoting bone healing.

Keywords: Guided bone regeneration, chitosan, electrospinning, raspberry ketone, macrophage
phenotypes, immunohistochemistry
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CHAPTER 1
INTRODUCTION
Statement of Clinical Problem

Resorption of alveolar bone in patients with periodontal diseases, craniomaxillofacial
injuries and tooth extraction who need dental implants, is detrimental to the structural,
functional, and esthetic outcomes of dental implant treatment. Bone grafting is often required in
such cases to restore the maxillary or mandibular bones to sufficiently hold the implants in place.
However, the major problem with the effectiveness of bone grafting procedures is overgrowth or
invasion of surrounding soft tissues that grow faster than the healing bone into the graft sites,
resulting in inadequate bone regeneration. Guided bone regeneration (GBR) technique, which is
the use of barrier membranes, has been developed to prevent the ingrowth of the faster-growing
soft tissues by covering and protecting bone grafted spaces during the bone regeneration process.
In GBR procedure, the membrane is placed on top of the grafting material, between the soft
tissue and bone, allowing for the regeneration of necessary bone volume needed for an optimal
implant placement.
An ideal membrane’s characteristics may differ depending on the procedure and clinical
use; however, a GBR membrane should fulfill some main criteria in general, including
biocompatibility, the ability to create space, cell occulsiveness, tissue integration, clinical
manageability, and adequate mechanical properties [1]. Current GBR membranes, widely used in
clinical practice, are either non-resorbable or resorbable. However, there are several
shortcomings and a relatively high (23-50%) rate of complication which can lead to inadequate
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bone regeneration and longer treatment times [2]. Non-resorbable membranes, made of expanded
polytetrafluoroethylene (ePTFE), demonstrate desirable biocompatibility, hydrophobicity, and
mechanical stability to be effective barriers to soft tissues. However, a second surgery is required
for removing the membrane from the grafting site which increases costs and risks damage to the
newly regenerated bone tissue [1, 3]. Resorbable GBR membrane materials, consist of collagen
or aliphatic polyesters, gradually degrade, and do not require a second surgery for the removal of
the membrane as in the case of non-resorbable membranes. However, occasionally the premature
degradation of these membranes can limit the quantity of bone regeneration. Moreover, aliphatic
polyester membranes such as poly(lactic acid) produce acidic degradation products that cause
inflammation, foreign body responses and cytotoxicity, and interfere with adequate bone
formation in the graft site [4].
To enhance the bioactive properties of the GBR membranes, attempts have been made to
supplement the membranes with bioactive therapeutic molecules such as bone morphogenetic
protein-2 (BMP-2). BMP-2 is a bone signaling molecule that can accelerate bone growth through
inducing osteogenic differentiation of mesenchymal stem cells (MSCs) and pre-osteoblasts.
However, BMP-2 is extremely expensive, shows poor release patterns, and has been associated
with side effects such as ectopic bone formation, ankylosis, and bone resorption [5, 6].
Therefore, there is a need to overcome the limits of current GBR materials and develop
membranes capable of providing both effective barrier function and bone regeneration.
Electrospun chitosan membranes (ESCM) have demonstrated several encouraging
advantages over current GBR membrane materials such as biocompatibility and controlled
degradation properties [7]. Chitosan has been shown to be capable of stimulating the wound
healing process and osteogenesis. Moreover, the biomimetic nanofiber structure of electrospun
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chitosan membranes provides an interconnected porous network with high surface area that
allows for enhanced cell attachment, migration, and fluid exchange. It is also potentially
advantageous for drug loading and delivery [8].
For healing to occur after implantation of graft and membrane materials, the acute
inflammation stage needs to subside in favor of proliferation and function of cells responsible for
elaboration of new tissue matrix. On a cellular level, macrophages play a crucial role in all
phases of wound healing process. In the early wound stages, macrophages direct the removal of
damaged tissues and bacteria from the wound site. These macrophages are referred to as proinflammatory (M1 phenotype) macrophages. As the wound heals, the local macrophage
population transitions from predominantly pro-inflammatory M1 phenotypes to antiinflammatory M2 phenotypes for supporting and directing the formation of new blood vessels
and tissues [9]. Therefore, with respect to the crucial role of macrophages in healing process,
strategies to facilitate the transition of M1 macrophages to the M2 phenotype have gained more
traction [10].
One strategy to promote macrophage transition is to use locally delivered therapeutics
that help stimulate macrophage polarization. The aim of this study was to investigate the local
delivery of a natural anti-inflammatory compound, raspberry ketone (RK), into a bone defect site
using ESCM.. Raspberry ketone is a hydroxy-phenolic compound obtained from raspberries,
inexpensive, readily available as a nutraceutical, and with proven effect on reducing
inflammatory reaction [11]. RK has been shown to reduce the production of nitric oxide (NO) by
activated macrophages in vitro as well as initiate differentiation of stem cells into osteoblasts
[12, 11]. Decreasing NO level due to the antioxidant activity of RK as well as reduced M1
activities can be related to increasing release of IL-10 and promotion of M2 pro-healing
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macrophages activity. It is suspected the pleiotropic anti-inflammatory characteristic of RK
promotes transition of pro-inflammation M1 phenotype to pro-healing M2 phenotype leading to
rapid healing and bone regeneration in GBR applications.
Hypothesis and Research Objectives
The goal of this study is to determine the impact of RK loaded ESCM on bone healing in
a rat calvarial defect model. It is hypothesized that RK loaded chitosan membranes would
enhance the healing process by modulating macrophage transition from M1s (pro-inflammatory)
to M2s (pro-healing). The key importance of the current project is being able to correctly identify
M1 and M2s in the tissues in order to evaluate macrophage polarization in response to
implantation of RK-loaded ESCM. This will then allow to answer the questions:
1- Whether RK has any effect on transition of macrophage phenotypes
2- If so, does RK promotes pro-healing M2s?
3- Whether promoting M2s lead to improved healing
If successful, local delivery of raspberry ketone might provide a new strategy for promoting
healing in dental defects without significant complications and costs associated with the use of
growth factors.
Therefore, the specific objectives of this work were:
-

To identify effective immunohistochemical staining methods to correctly distinguish
M1 and M2s within the tissue surrounding membranes

-

To quantify M1 vs M2 cells in the immunohistochemically stained tissue sections

-

To determine the effect of RK delivered through ESCMs on M1 to M2 transition
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CHAPTER II
LITERATURE REVIEW
Craniomaxillofacial Bone Loss

Periodontal (gum) disease is an infection of the tissues surrounding the teeth that
damages gums and can destroy the jawbone. Diabetes, smoking, a weakened immune system,
and poor oral hygiene are the most important factors that increase one’s risk for gum disease
[13]. In the early stages of gum disease, known as gingivitis, the soft tissue becomes inflamed
developing red, swollen and bleeding gums. Gingivitis is the only stage of periodontal disease
that is reversable and can be treated through a daily routine of good oral care as well as
managing health conditions that impact dental health [14]. In the more advanced periodontal
disease, periodontitis, not only gums are affected but also the structure of tooth-supporting bones
is compromised. Periodontal disease is the leading cause of tooth and/or bone loss in the jaw [15]
affecting mastication, speech, and appearance of patients. Nearly 42% of adults ages 30 years or
older show signs of gum disease in the USA. However, severe gum disease affects about 9 % of
adults ages 20-64 and 17.2% of adults over the age of 65 [16]. Tooth and bone loss may also
occur due to injuries such as assaults, traumatic accidents, or military conflicts. Assaults are the
most common cause of traumatic facial injury, making up about 70% of cases [17]. Dental
implants have become an increasingly popular restorative therapy for replacement of tooth loss
in craniomaxillofacial injuries and periodontal diseases. It is estimated that about 5,000,000
dental implants are placed per year in the USA, and the global dental implants market size
valued at USD 4.6 billion in 2019, is expected to grow at a compound annual growth rate
(CAGR) of 9.0% from 2020 to 2027 [18].
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Bone Grafting

Bone loss in patients with periodontal diseases, craniomaxillofacial injuries and tooth
extraction, hinders the long-term success of dental implants. In such cases, bone grafting is often
required prior to dental implantation, to regenerate the maxillary or mandibular bones for
sufficiently support of the implants in place. Bone regeneration using grafting materials may take
place through either of three mechanisms including osteogenesis, osteoinduction and
osteoconduction [3]. Osteogenic materials directly provide cells that contribute to the growth of
new bone, including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, and osteocytes.
Osteoinductive materials are those containing factors that induce bone growth by stimulation of
stem cells to differentiate into a bone-forming lineage, while osteoconductive materials only
provide a structural framework for bone growth [19]. Bone graft materials can be broadly
divided into four major types: autogenous graft, allograft, xenograft, and alloplasts, each having
one or more of the aforementioned mechanism of actions [19]. Autograft is bone transferred
surgically from one part of the body to another part, in the same patient. Autografts contain
growth factors, proteins, and other bioactive materials necessary for osteogenesis. Therefore,
autografts are considered the gold standard among graft materials due to high efficacy and
success rate; but are criticized for the possible resultant donor site morbidity and lack of
sufficient graft volume. Allograft is bone harvested from an individual rather than the one who
receives the graft, mostly taken from cadavers and used either freshly frozen or freeze-dried. The
main advantage with allografts is reduced host morbidity avoiding a secondary surgical donor
site. Also, the lack of graft volume is not an issue with allografts due to abundant supply of
grafting materials. However, allografts are not osteogenic, and the process of bone regeneration
usually takes longer than that of autografts. Furthermore, there is a concern for the possibility of
6

disease transmission with contaminated allografts. However, stringent donor selection and
allograft processing can make the risk extremely low [3, 20]. Xenografts are obtained from other
species and transplanted into the human’s body. Xenografts are readily available and
demonstrate well documented success [21]. The possible challenges for xenografts include a
potential risk of viral or bacterial infections, low resorption rate and increased host immune
response due to foreign body reaction of other species tissue [22]. Finally, alloplasts are
synthetically made material to be used in the human’s body as an alternative to bone grafts.
Although there are many compositions available as alloplasts, commonly used materials include
synthetic hydroxyapatite and tricalcium phosphate (TCP), calcium carbonate, calcium sulfate,
bioactive glass, and polymers such as poly lactic acid (PLA), poly glycolic acid (PGA) and their
copolymers as well as composite systems such as PLA/HA and PLA/ TCP [23]. These synthetic
compositions overcome the common problems with organic materials such as limited supply and
disease transmission. However, they do not exhibit osteoinductive properties, though do possess
osteoconductive properties, that allow them to serve as a scaffold for enhanced bone tissue repair
and growth [3].
A dental implant is often placed several months after the grafting procedure, allowing for
an adequate bone regeneration to support the dental implant [24]. Although the success rates for
dental implants are high, up to 10% failures are associated with bone quantity and/or quality
[24]. The major problem with the effectiveness of bone grafting procedures is overgrowth or
invasion of surrounding soft tissues that grow faster than the healing bone into the graft sites
[25]. Migration of soft tissue into the site results in inadequate bone regeneration for an optimal
implant anchorage and stability [25]. A dental implant failure mandates immediate implant
removal followed by repairment of the implant’s site for further implantation. Such additional
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procedures not only adversely affect the satisfactory function and aesthetics of the implantation,
but cost both patients and clinicians additional time, expenses, and stress [26].

Guided Bone Regeneration

Guided bone regeneration (GBR) is a surgical technique that uses barrier membranes to
direct bone growth at defect sites with insufficient volumes of bone. It allows for the
regeneration of necessary bone volume needed for an optimal implant placement. GBR
membranes prevent ingrowth of the faster-growing soft tissues by covering and protecting bone
grafted spaces during the bone regeneration process [8]. The membrane is placed on top of the
grafting material, between the soft tissue and bone. The soft tissue is then pulled back over the
site and closed (Figure 1).

Figure 1: Guided bone regeneration procedure using barrier membranes [27]
1. The tooth socket is thoroughly cleaned of all infected and inflamed tissues, 2. Bone grafting
material is placed into the socket, 3. GBR membrane is usually placed over the grafted material
to enhance bone growth, 4. Sutures placed into the gum that allow healing of the surrounding
soft tissue.

8

Membranes for Guided Bone Regeneration

Current commercially available GBR membrane materials consist of expanded
polytetrafluoroethylene (ePTFE), collagen, cross-linked collagen or aliphatic polyesters
including poly(lactic acid) (PLLA) and poly(glycolic acid) (PLGA) [28, 29]. Although ePTFE
membranes are highly mechanically stable, hydrophobic, and effective barriers to soft tissues,
they are not resorbable. Therefore, a second surgery is required for removing the membrane from
the grafting site which increases costs and risks of damage to the newly regenerated bone tissue
[28, 29]. Collagen, PLLA and PLGA membranes are bioresorbable and do not need surgical
removal. However, collagen membranes not only are less mechanically stable than ePTFE, but
also degrade too quickly to provide adequate barrier function for bone regeneration [29]. PLLA
and PLGA are synthetic resorbable GBR membranes. These membranes are advantageous due to
some properties such as degradation rate and mechanical properties that can be customized by
modifying chemical composition and structure of the polymers. However, they cause
inflammatory, foreign body responses and cytotoxicity due the accumulation of their acidic
degradation products. This results in a limited bone formation in the graft site [4].
While current GBR membranes are widely used, there are several short-comings and a
relatively high (23-50%) rate of complications [2]. Severe inflammation is a serious concern that
can potentially lead to exposure of the membrane, infection, and premature degradation, all of
which inhibit adequate bone for implant placement and require intervention [30]. GBR
membranes are often supplemented with bioactive therapeutic molecules such as bone
morphogenetic protein-2 (BMP-2) to augment healing of bone grafting sites [31]. BMP-2 is a
bone signaling molecule that induces osteogenic differentiation of mesenchymal stem cells
(MSCs) and pre-osteoblasts [31]. Although its potential for enhancing bone formation associated
9

with dental implants is fascinating, the optimal technology for adsorbing or incorporating BMP-2
into/onto an implant surface with desirable release kinetics has not been determined yet [31]. The
release rate is affected by the degree of porosity and interconnectivity of pores, as well as the
degradation properties of the material onto which it is loaded. The unfavorable dosing and
release profiles of BMP-2 can cause adverse reactions such as ectopic bone formation,
bone/tooth root resorption and ankylosis [32]. Other growth factors such as platelet- derived
growth factor (PDGF) transforming growth factor β, (TGF- β) vascular endothelial growth factor
(VEGF) have also been investigated for use in bone regeneration [33]. However, the cost of
manufacturing growth factors is extremely high which limits the use of these proteins.
The ideal membrane characteristics may differ depending on the procedure and clinical
use. For instance, being resorbable is not always desirable. For an application like ridge
augmentations, a surgeon may prefer a titanium mesh or a titanium-reinforced membrane due to
their superior rigidity and stability in comparison with resorbable membranes [27]. However, an
ideal membrane should fulfill some main criteria in general, including biocompatibility, the
ability to create space, cell occulsiveness, tissue integration and easy handling. The
morphological structure, biological stability, and the ability to activate growth factors are also
key factors that must be considered to achieve optimum bone volume [34].
1- Biocompatibility: Biocompatibility is the most important requirement for a GBR membrane
allowing the membrane to function in the body without causing any detrimental local or
systematic responses. The interaction between the membrane and tissue should positively affect
the surrounding tissue toward the healing of the defect. A desirable membrane-tissue interaction
can support cell attachment, growth, and differentiation. Moreover, if the membrane is
resorbable, it should degrade into non-toxic components [34, 35]. Overall biocompatibility of
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scaffolds and their capability to integrate with surrounding tissue is important in providing
structural stability.
2- Space maintenance: The membrane should be compression resistant to prevent underlying
graft from collapsing. The adequate stiffness of the membrane allows to maintain space for new
bone formation [27, 35].
3- Cell occulsiveness: The surface of the membrane should prevent soft/fibrous tissues from
invading the graft site, but at the same time allow oxygen, fluids, and bioactive substances for
cell growth to reach the defect. It directly correlates to the membrane porosity. A larger pore size
may inhibit bone formation by allowing the overpopulation of faster-growing cells. When the
pore size is too small, cell migration is limited for collagen deposition and the formation of
avascular tissue results [34, 35].
4- Easy – handling: A membrane should not be too stiff because it would not integrate with the
tissue or could create dehiscence of the soft tissues; or too malleable making it difficult to work
with [34, 36].
5- Predictable degradation rate: Degradation rate is one of the most important parameters for
resorbable membranes. The resorption time of the membrane should coincide with the
regeneration rate of bone tissue to maintain its barrier function for adequate new bone formation
[35].
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Electrospun Chitosan Membranes

Chitosan
Chitosan is a linear polysaccharide derived from chitin, a natural biopolymer found in
crustacean shells and insect exoskeletons. Chitosan and its derivatives possess characteristics
such as biocompatibility, controllable non-toxic degradation properties, ability to stimulate
wound healing, and osteoconductivity which are advantageous for development as biomaterials
for GBR applications. Chitosan degrades into short chain oligosaccharides and simple sugars,
which are non-acidic and exhibit no cytotoxicity, unlike the degradation products associated with
synthetic polymers [37]. Studies have shown that chitosan exhibits some anti-tumor,
antimicrobial, and antioxidant properties [38, 39]. Moreover, the polycationic carbohydrate
structure of chitosan makes it attractive for drug delivery, and that mimics hyaluronic acid, an
extracellular matrix molecule [38].
Important properties of chitosan such as solubility, biodegradability, bioactivity, and
mechanical properties are closely associated with its molecular weight and the degree of
deacetylation [40, 41]. Chitosan is obtained from the deacetylation of chitin which is a process of
removing acetyl groups from chitin and substitution of reactive amino groups (NH2) as shown in
Figure 2. The degree of deacetylation (DDA) determines the content of free amino groups in the
structure [42]. Chitin has a DDA of 0% and is insoluble in water and most organic solvents. As
DDA increases up to ranges of approximately 60%, the swelling and solubility of chitosan
increases, mechanical stiffness and strength decrease, and its structure becomes less crystalline
leading to increasing degradation rate [43]. As DDA continues to increase, crystallinity begins to
increase again, leading to decreases in swelling/solubility, increases in mechanical properties and
decreasing degradation rates [44]. Chitosan degree of deacetylation (DDA) has been cited as an
12

important parameter that determines many physiochemical and biological properties of chitosan.
For example, Freier et al. showed that prolonged degradation times and enhanced cell adhesion
was achieved using chitosan with a DDA close to 0% or 100% while chitosan with intermediate
DDAs exhibited faster degradation rates, but limited cell adhesion [45]. Hidaka et al. reported
that chitosan membranes between 65 and 80% DDA elicited marked inflammatory reactions that
subsided in time with degradation of the films, granulation tissue formation, and osteogenesis
while membranes made of 94% DDA chitosan showed minimal degradation, mild inflammation
and minimal osteogenesis [46]Molecular weight of chitosan is another important factor that
affects chitosan’s biological and physical properties such as bioactivity, crystallinity,
degradation, tensile strengths, and viscosity of the chitosan solution [41]. The molecular weight
(MW) of chitosan is dependent on the initial source material (shrimp, crab, fungi, etc.) and can
decrease with processing to increase DDA [44]. Nuthanid et al. noted that tensile strength and
moisture adsorption of chitosans with high molecular weights (600–1000 kDa) were significantly
greater than those with similar DDA but lower molecular weights (50–60 kDa) [47]. Huang et al.
reported that the uptake of chitosan nanoparticles by cultured fibroblasts was mainly attributed to
DDA, but molecular weight also played a role [48]. Chemical modification of chitosan using
techniques such as acylation, alkylation, sulfation, hydroxylation, quaternization, esterification,
graft copolymerization, and etherification can widen its applications and effects [49]. Moreover,
chitosan can be easily fabricated into multiple forms including fibers, nanoparticles,
microspheres, hydrogels, films, sponges, paste and scaffolds due to its nature which is soluble in
dilute organic acids [40, 50]. Chitosan’s versatility, availability as well as its low cost are some
other fascinating reasons beside its physiochemical and biological properties, that make chitosan
appealing to be used as biomedical regenerative material.
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Figure 2: Chemical structure of chitin and chitosan

Electrospinning
Electrospinning is a method that uses electrical force to make continuous micro- to nanoscale fibers out of polymer solutions, biomimicking the native extracellular matrix structural
scale range. The most typical method of collecting the electrospun fibers is on a grounded,
collecting plate. Because of the randomness of the unstable fiber jet, a highly porous, nonwoven
fibrous sheet with a large surface-volume ratio is collected [51]. An electrospinning setup
typically consists of three components: a high voltage power supply (5-30kv, low current), a
polymer reservoir and spinneret (commonly a syringe with a conductive dispensing needle), and
a grounding target serving as a collector (Figure 3). The voltage source supplies a charge to the
spinneret, creating an electric field between the grounded target and the positively charged
capillary filled with a polymer solution. When the electrostatic charge becomes larger than the
surface tension of the polymer solution at the capillary tip, a fine polymer jet is drawn out of the
spinneret travelling toward the collector in the form of nanofibers. The fiber morphology is
14

associated with some electrospinning parameters during the fabrication. Following parameters
may greatly affect the thickness of nanofibers and their consistency (bead formation):
Environmental parameters (temperature and humidity), processing parameter (voltage, distance
between the collector and tip, flow rate) and polymer solution properties (viscosity, molecular
weight, conductivity) [52]. Scaffold microporosity is controlled by changing critical factors such
as substrate thermal conductivity (copper, glass, insulated glass), solvent type (dichloromethane,
chloroform, and tetrahydrofuran), polymer concentration (3–15% by weight) and relative
humidity of the environment (0–85% relative humidity) [53]. Table 1 shows a summary of the
electrospinning parameters and their effects on fiber morphology.
Electrospun chitosan membranes (ESCM) have shown great potential for guided bone
regeneration applications [7]. The microporous structure of electrospun fibers along with the
high surface area to volume ratio are favorable for tissue engineering applications. The nanoscale
fibrous structure of electrospun chitosan membranes mimics the native fibrillar structure of
extracellular matrix to support cell attachments, growth, and migration, and provides the
advantage of having increased surface area for drug delivery [8]. Several studies have
demonstrated that electrospun chitosan membranes facilitated new bone formation in critical size
bone defects [50, 54]. The nanofiber structure also results in porous structure for the
communication between osseous and epithelial tissue compartments, and nutrient exchange
while remaining cell occlusive [55].

15

Figure 3: Schematic of a basic electrospinning set up [52]
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Table 1: Electrospinning parameters and the effects on fiber morphology [56, 51]
Parameters
Voltage

Effects on fiber morphology
-

Processing parameters

Distance between the
needle and collector

-

Flow rate

-

Solution Parameters

Polymer concentration andSolution viscosity
-

Molecular weight

-

Conductivity

-

The critical value of applied voltage to form uniform
nanofibers varies from polymer to polymer
Too high voltage → formation of beads
Correlation between voltage and fiber diameters is
ambiguous.
At distances either too close or too far → presence of beads
A minimum distance is required to obtain dried fibers
Desirable distance between the needle tip and collector varies
from polymer to polymer.
A critical flow rate to achieve uniform beadless nanofibers
varies from polymer to polymer.
Lower flow rate → fibers with smaller diameters, a minimum
flow rate maintains the balance between the leaving
polymeric solution and replacement of that solution with a
new one during jet formation.
High flow rate → formation of beads, production of fibers
that were not dry upon reaching the collector
A critical value of the concentration/viscosity to obtain
beadless nanofibers varies from polymer to polymer.
Low concentration of polymeric solution → beads formation
Increased concentration → increased viscosity → increase in
fiber diameters, decrease in beads
Increased concentration beyond the critical value →hamper
the flow of the solution through the needle → defective or
beaded nanofibers
Increase in polymer molecular weight → reduction of the
number of beads and droplets
Low conductivity → no charge at the surface of the droplet →
no electrospinning
Increase in conductivity → smaller fiber diameters, aiding the
production of uniform bead-free fibers

Environmental Parameters

Humidity
-

The effect of the humidity on nanofibers diameter is
dependent on the chemical nature of the polymer.
Increased humidity → appearance of circular pores on the
fibers

Temperature
-

Increased temperature → increased evaporation of the
solvent→ decrease in solution viscosity → smaller fiber
diameters
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GBR Induced Healing Process

After the implantation of the GBR membrane, the healing process begins in a sequential
fashion which is characterized by distinct, but overlapping phases including inflammation,
proliferation, and remodeling [57]. The inflammatory phase prepares the wound bed for the
growth of new tissue, involving phagocytosis and removal of bacteria and debris, as well as the
release of chemoattractant to facilitate the tissue repair. The inflammatory phase may last hours
to days, and then progressing into proliferative stage which involves elaboration or initial
extracellular tissue matrix, angiogenesis, granulation tissue formation and epithelialization to fill
and cover the wound. Proliferative phase lasts days to weeks followed by remodeling of the
initial extracellular matrix into mature tissues within months [57]. For a successful and efficient
healing after grafting and membrane implantation, all phases of this process must occur in the
proper sequence and time frame [9]. Macrophages play multiple critical roles in the process of
transition from acute inflammation to wound closure/healing. In the early wound, macrophages
release cytokines that promote the inflammatory response including nitric oxide (NO),
interleukins 1 and 6 (IL-1, IL-6), TNF- α, and IFN-γ that direct the removal of damaged tissues
and bacteria from the wound site. These macrophages are referred to as pro-inflammatory (M1
phenotype) macrophages. As wound heals, the local macrophage population transitions from
predominantly pro-inflammatory M1 phenotypes to anti-inflammatory M2 phenotypes that
produce factors such as IL-10 and TGF-β at pro-healing state for supporting and directing the
formation of new blood vessels and tissues [9]. Figure 4 schematically shows the role of
macrophages in wound healing process.
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Figure 4: The role of macrophages in wound healing [9]

Failure to transition from inflammation to pro-healing state will lead to chronic
inflammation resulting in continued tissue damage, poor or incomplete bone regeneration and
clinical outcomes [30, 9]. Causes of chronic inflammation can be related to non-biocompatible or
toxic materials, degradation or leachable products, infection or mechanical mismatch resulting in
irritation. [9, 58]. Although, the initial presence of M1 is crucial for a successful healing, the
prolonged presence of the M1 macrophages, or the imbalance of M1 over M2 macrophages can
disrupt tissue repair and regeneration. Moreover, if M2 macrophages remain for too long in the
defect site, excessive collogen formation results in fibrosis and scar tissue formation (Figure 5)
[9, 59]. It is reported that the success of biomaterial-mediated bone formation is depended on the
efficient and timely switch from M1 to M2 phenotype during bone healing, while a prolonged
M1 phase may result in fibrous encapsulation and failure of bone regeneration [60]. Therefore,
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biomaterials capable of modulation of macrophage polarization are promising for bone
regeneration [61].
Although macrophages are traditionally divided into classically activated (M1) and
alternatively activated (M2) macrophages, there are several different subsets of macrophages,
defined beyond the confines of two distinct categories of simply M1 and M2s. In fact,
macrophages polarize within a spectrum of phenotypes ranging from pro-inflammatory (M1) to
wound healing phenotypes (M2c) (Figure 6). Each macrophage subtype is defined based on cell
surface markers, cytokine, growth factor, chemokine production, and its function in the wound
healing cascade. However, since macrophages polarize along the spectrum between M1 and M2,
they may express multiple and often overlapping markers which reflects the complexity of the
healing process and can create challenges in attempting to identify specific macrophage
subtypes. [62]. Table 2 identifies the different names and markers for each macrophage
phenotype. The table is not comprehensive, and it is important to note that marker expression for
each phenotype can vary from study to study.
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Figure 5: Balance of macrophage phenotypes through tissue repair and angiogenesis
a) Sequential presence of M1 and M2 macrophages for a normal tissue repair b) Tissue healing
impairment due to an imbalance of either phenotype [59]

Figure 6: The spectrum of macrophages differentiation and polarization [62]
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Table 2: Macrophage phenotypes, surface markers and characteristics [9, 62, 63, 64]
Phenotype

M1

Other
nomenclature

Classically
activated,
pro-inflammatory

Stimulation/Activation

IFN-gamma
LPS
GM-CSF

Markers

Other notes

Surface:
CD86, CD80, CD68, MHC II,
IL-1R, TLR2, TLR4, iNOS,
SOCS3, CCR7, HLA-DR
Cytokine Secretion:
TNF-α, VEGF, IL-1β, IL-6, IL12, IL-23
Chemokine Secretion:
CCL10, CCL11, CCL5, CCL8,
CCL9, CCL2, CCL3, CCL4

abundant and
persistent in
chronic wounds;
activated in vitro
by LPS,
peptidoglycans and
pro-inflammatory
cytokines

All M2-phenotypes collectively: alternatively activated; anti-inflammatory
M2

M2a

M2b

M2c

M2d

Alternatively
activated, wound
healing

Type 2;
regulatory

Deactivated,
hybrid, proresolving

---

Surface:
CD163, CD206, CD209, MHC
II, SR, CD200R, TGM2,
DecoyR, IL-1R II
Mouse only:
Ym1/2, Fizz1 (RELMα), Arg-1
Cytokine Secretion:
IL-10, TGF- β, IL-1RA, PDGF,
TIMP3
Chemokine Secretion:
CCL17, CCL22, CCL24

aid in ECM
formation,
angiogenesis

ICs
TLR4
IL-1R

Surface:
CD86, MHC II
Cytokine Secretion:
IL-10, IL-1, IL-1 β, IL-6, TNFα
Chemokine Secretion:
CCL1

similar to M1
macrophages, but
dampen
inflammation

IL-10
TGF-beta
GCs

Surface:
CD86, CD163, CD206, TLR1,
TLR8
Cytokine Secretion:
IL-10, TGF- β, MMP9
Chemokine Secretion:
CCR2
Surface:
VEGF

IL-4
IL-13
Fungal and Helminth
infection

IL-6
LIF
Adenosine

Cytokine Secretion:
VEGF, IL-10, IL-12, TNF- α, TGFβ
Chemokine Secretion:
CCL5, CXCL10, CXCL16
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involved in
vascular and matrix
remodeling

pro-angiogenic;
activated in vitro
by stimulating
adenosine and tolllike receptors

Raspberry Ketone

Raspberry ketone (RK) is a natural phenolic compound derived from raspberries. It is
used in perfumes, candles, and food flavoring due to its sweet aroma [65]. Raspberry ketone is
available in the market as a dietary supplement and shown to have anti-obese function and fatburning properties. It has been demonstrated that RK stimulates the metabolism of adipose
tissues and inhibits the absorption of dietary fat through small intestine [66]. Recently, RK has
been shown to initiate differentiation of stem cells into osteoblasts, in vitro. Takata et al. treated
confluent C3H10T1/2 cells with 10-100μg RK in culture medium containing either all-transretinoic acid (ATRA) or recombinant human bone morphogenetic protein (rhBMP)-2 protein as
an osteoblast-differentiating agent. RK in the presence of either ATRA or rhBMP-2 increased
alkaline phosphatase (ALP) activity in a dose dependent manner. RK in the presence of ATRA
also increased other osteogenic markers including TGF-β, osteocalcin, and collagen type 1,
compared with ATRA only [12], suggesting that RK enhances the differentiation of stem cells
into osteoblasts, and may contribute to promoting new bone growth. RK has also shown to have
some anti-inflammatory characteristics, reducing the production of nitric oxide by activated
macrophages [11]. Another in vitro study has examined the potential of RK in promoting the
transition of macrophages to pro-healing M2 phenotypes. In this study, monocytes/macrophagelike cells (RAW 264.7) were treated with different concentration of RK including 60, 120 and
240 μg RK/ml medium, to evaluate its effects on inflammatory and non-inflammatory cytokine
expression. Results showed that RK at 120 μg/ml was able to reduce proinflammatory cytokines
(TNFα, IL-1β) and increase anti-inflammatory/pro-healing cytokine (IL-10) compared to other
concentration of RKs [67]. These results indicate that RK may augment the wound healing
process and promote bone cell differentiation.
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RK solubility in ethanol makes it easy to be loaded onto electrospun GBR membranes
for drug delivery approaches. The RK dissolved in ethanol can be loaded on to a GBR
membrane, and once the ethanol evaporates, the RK is left adsorbed to the surface of the fibers
of the membrane for localized release. The availability and affordability of RK, as well as its
potential anti-inflammatory/prohealing characteristics may provide a new strategy for promoting
healing in bone defects, without significant complications and costs associated with the use of
growth factors. It is hypothesized that the pleiotropic anti-inflammatory characteristic of RK
promotes facilitated transition of pro-inflammation M1 phenotype to pro-healing M2 phenotype
leading to rapid healing and bone regeneration in GBR applications.

In this study, RK at two different doses including 100 μg and 500 μg were loaded onto
ESCM membranes and used to cover 5-mm diameter rat calvarial defects. Animals were
euthanized at 1, 2 and 4 weeks and histological sections of defects were immunohistochemically
stained to assess the presence of macrophages and polarization phenotype in response to
membrane implantations.
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Chapter III
IN VIVO EVALUATION OF MACROPHAGE POLARIZATION IN RESPPONSE TO
RASPBERRY KETONE-LOADED CHITOSAN MEMRANES

Introduction
Bone loss in patients with craniomaxillofacial injuries, periodontal diseases and tooth
extraction causes complications of masticatory function, speech and altered aesthetics. Bone
grafts are extensively employed in current reconstructive techniques to restore the bone defects.
However, the overgrowth or invasion of epithelial/fibrous tissues interferes with bone grafting
procedures. To overcome this issue, guided bone regeneration membranes have been
investigated to augment healing by covering and protecting bone grafted spaces from migration
of soft tissues as well as providing an osteogenic environment for enhancing bone regeneration
[25]. The concept of GBR was introduced around the 1950s, used for both spinal fusion and
maxillofacial regeneration applications [25].
Chitosan has become a widely researched biomaterial in regenerative medicine due to its
favorable properties such as nontoxicity, osteoconductivity, biodegradability, and
biocompatibility [38]. Nanofibrous electrospun chitosan membranes, have shown encouraging
potential for guided bone regeneration applications [50]. There have been multiple studies that
reported new bone formation in critical-sized defects using these electrospun chitosan
membranes as a GBR material [50, 54, 7, 68]. Moreover, the biomimetic nanofiber structure of
electrospun chitosan membranes (ESCM) provides an interconnected porous network with high
surface area that allows for enhanced cell attachment, migration, and fluid exchange. It is also
potentially advantageous for drug loading and delivery [55].
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For healing to occur after implantation of graft and membrane materials, the acute
inflammation stage needs to subside in favor of proliferation and function of cells responsible for
elaboration of new tissue matrix [69]. On a cellular level, macrophages play a crucial role in all
phases of wound healing process. As wounds heal, the local macrophage population transitions
from predominantly pro-inflammatory (M1 phenotypes) to anti-inflammatory (M2 phenotypes).
During the initial inflammatory stage, M1 macrophage phenotypes express pro-inflammatory
factors such as nitric oxide (NO), interleukins 1 and 6 (IL-1, IL-6), TNF- α, and IFN-γ that direct
the removal of damaged tissues and bacteria from the wound site. Eventually at the pro-healing
stage, M2 macrophage phenotypes release factors such as IL-10 and transforming growth factor
(TGF-β) for supporting and directing the formation of new blood vessels and tissues [9]. Failure
to transition from the inflammatory to pro-healing state will lead to chronic inflammation
resulting in continued tissue damage, poor or incomplete bone regeneration and clinical
outcomes [30, 9]. Therefore, with respect to the crucial role of macrophages in healing process,
the strategies to help facilitate the transition of macrophages to promote M2 phenotype has
gained traction.
Raspberry Ketone (RK) is a natural phenolic compound found in raspberries and is
commercially available as a nutraceutical because of its reported antioxidative properties and
other health benefits [65]. RK has shown to have anti-inflammatory characteristics, reducing the
production of nitric oxide by activated macrophages [11]. It has been shown that RK at some
doses was able to reduce proinflammatory cytokines (TNFα, IL-1β) and increase antiinflammatory/pro-healing cytokine (IL-10) released by monocytes/macrophage-like cells (RAW
264.7) in vitro, promoting the transition of macrophages to pro-healing M2 phenotypes. [67].
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These results suggest that RK may augment the wound healing process by promoting transition
of macrophages to pro-healing M2 phenotypes at defect sites.
The aim of this study is to locally deliver the natural anti-inflammatory/pro-healing
compound, raspberry ketone (RK), into a periodontal or alveolar ridge defect site using ESCM to
promote soft tissue healing and bone regeneration by stimulating the transition of the
macrophage phenotype from pro-inflammation (M1 macrophages) to pro-healing (M2
macrophages). To determine the effects of RK-loaded electrospun chitosan membranes on
inflammation and initial bone healing, we evaluated the macrophage polarization in response to
the membranes in vivo, using a rat calvarial defect model. The hypothesis to be tested was that
RK will facilitate the transition of M1 to M2 macrophages resulting in an accelerated wound
healing process.

Material and methods

Experimental Design
Tissue blocks were obtained from prior rat study that used the hexanoic-anhydride
modified ESCM loaded with 0, 100 and 500 μg RK to heal 5 mm-diameter calvarial defects [70].
Briefly, hexanoic-anhydride ESCM were prepared according to the procedure described by
Murali et al [71].. Membranes were punched into 5 mm-diameter disks, loaded with two
different concentrations of RK, 100 and 500 μg RK, to be implanted in rat calvarial defects.
ESCM loaded with either 100 or 500 μg RK, and a control group which was ESCM without RK
were implanted in rat calvarial defects as follows. Each animal was implanted with two ESCM,
one ESCM loaded with RK and one without RK. Eight rats (n=8) were implanted per each test
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group per time point (n=8). The membranes and surrounding tissues were explanted at 1-, 2- and
4-weeks post implantation for histology.

Immunohistochemistry
Paraffin embedded rat calvarial sections from animals implanted with electrospun
chitosan membranes with and without RK were immunohistochemically stained for macrophage
phenotype markers, CD68 (PAN-marker), CD206 (M2-marker) and iNOS (M1-marker). Three
serial sections of each animal (thickness =5micron) were used, each section stained for one of the
macrophage markers. For immunostaining, paraffin embedded sections were first deparaffinized
with xylene, then rehydrated with graded ethanol and rinsed with distilled water. Heat mediated
antigen retrieval was performed by incubating the sections in TRIS/EDTA Buffer (10 mM Tris
base, 1 mM EDTA solution, 0.05% Tween 20), for 30 minutes in a steamer or water bath.
Sections were allowed to cool to room temperature, then rinsed in PBS Tween 20, and incubated
in 0.3% H2O2 in methanol for 30 minutes to block endogenous peroxidase activity present in the
tissue followed by another 30-minute incubation with blocking buffer (10% normal horse serum
(NHS)/0.3% triton-X-100 in PBS) to prevent non-specific antibody binding. Overnight
incubation at 4° C in primary antibody diluted in 5% NHS/1% BSA with 0.3% Triton X-100 in
PBS was applied. After an overnight incubation with primary antibodies, sections were washed
with 0.05% Tween-20 in PBS before incubating for 12 minutes in secondary antibody diluted in
blocking serum and PBS. After washing, sections were covered with the streptavidin/peroxidase
complex for 6 minutes. Streptavidin/peroxidase complex was removed, sections were washed
and then each covered by DAB substrate solution for 1-5 minutes. In the last step, sections were
stained with Hematoxylin QS (Vector lab cat # H-3404) for 15 seconds, rinsed with tap water for

28

30 seconds followed by distilled water for 2 minutes, and dehydrated using 70% ethanol [2 min],
85% [2 min], 95% [2 x 2 min], 100% [2 x 2 min]. Eventually, sections were cleared in xylene
and mounted using mounting medium and a #1.5 cover slip.
The primary antibodies and their dilutions used in this study were as follows: rabbit antiCD68 polyclonal antibody (1:500, PA5-78996, Invitrogen), rabbit anti-Mannose Receptor
polyclonal antibody (1:1000, ab64693, Abcam), rabbit anti-iNOS polyclonal antibody (1:25,
ab15323, Abcam). The secondary antibody and its dilution used in this study was horse antirabbit antibody (1:20, PK-8800, Vector Laboratories).

Macrophage analysis
Images of stained sections were acquired at 20X using the stitching function of CellSens
software on an Olympus BX63 microscope. Immunohistochemistry image analysis, and
macrophages polarization evaluation were done using NIH Image J software. Macrophages were
counted and positively stained area against macrophage markers were measured within the
regions of interest, the inflammatory site around the membrane, through adjusting the threshold
of intensity [72].. All the analysis were done by a blinded observer. To normalize the data, the
total stained area or the number of cells counted in the ROI was divided by the area of ROI,
presenting the data as either percent of stained area, or the number of cells per unit area,
respectively.
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Statistical analysis
All data were presented as mean ± standard deviation. Statistical analysis was performed
in SigmaPlot 14.5, using ANOVA followed by post-hoc analysis to identify the statistical
differences between the groups over time. P<0.05 was considered significant.

Results

Representative images of sections with 100 μg raspberry ketone stained for all three
macrophage markers including CD68 (PAN), iNOS (M1) and CD206 (M2) are shown in Figure
7. The brown color shows the positive staining for each macrophage marker. The overall number
of macrophages was observed to decrease over the 4-week time period as a result of
inflammatory resolution. This conclusion was based on visual observations of the intensity of the
brown staining in the sections. Comparing the staining for the pro-inflammatory and pro-healing
macrophage phenotypes, visual observations suggest that more iNOS+ cells than CD206+ cells
are present one week post implantation. In the two-week sections, staining indicated that
macrophage populations were primarily anti-inflammatory M2 phenotypes. At week 4, the
overall number of macrophages was significantly decreased as the healing process transitioned to
the tissue proliferative and remodeling phases. It is noted though, some positive staining for
CD206 marker was still evident.
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Figure 7: Representative images of sections with 100μg RK stained for CD68 (PAN-marker),
iNOS (M1 phenotype marker) and CD206 (M2 phenotype marker). All magnifications are 20X.

Representative images of sections with 500μg raspberry ketone stained for all three
macrophage markers are shown in Figure 8. Visual observations for the 500 μg RK group were
generally similar to that for 100 μg RK group. Overall macrophage staining for the pan marker
declined over the 4-week period. There was more intense staining for iNOS+ than CD206+
macrophages at week one. Staining for CD206+ cells increased at week 2. However, as compared
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to the 100 μg RK group, staining for iNOS+ cells appeared to be more intense at the 2-week time
point. At week 4, there remained some positive staining for CD206 marker, the overall number
of macrophages present as low.
Visual observation of the images for the specimens without RK showed similar pattern as
100 and 500 μg RK groups within the 4-week time period. The overall staining intensities for
different macrophage markers were similar in appearance with those of 100 and 500 μg RK
groups.
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Figure 8: Representative images of sections with 500μg RK stained for CD68 (PAN-marker),
iNOS (M1 phenotype marker) and CD206 (M2 phenotype marker). All magnifications are 20X.

Figure 9 shows the results of the image analyses for the percent of area positively stained
for CD68+, iNOS+ and CD206+ macrophage cells at the 1-, 2- and 4-week post implantation time
points. The data generally confirm the visual observations of staining intensity patterns with
decreasing trend of CD68+ (Figure 9A) and iNOS+ (Figure 9B) staining macrophages over the 4-
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week time period and an increase in CD206+ (Figure 9C) staining cells from week 1 to 2, and
then a decreasing from week 2 to week 4.
For all three markers, 2-way-ANOVA were performed on percent of stained area to
identify differences in the main factors, a] treatment, based on amount of RK in the membranes,
and b] time, and if there were interactions between the main factors. For the CD68+ staining
(Figure 9A), analyses indicated that there was no significant difference between the treatments
(p=0.29), there was a significant difference over time (p=0.006) and there was no significant
interaction between the main factors (p=0.7). Post-hoc analyses indicated that the number of
CD68+ cells significantly increased from week 1 to 2 (p=0.015) and then a significant decrease
from week 2 to 4 (p=0.011).
Analyses for iNOS+ staining cells (Figure 9B) indicated that there was a significant
difference between the treatments based on the amount of RK loaded into the membranes
(p=0.046), over time (p<0.001) but there was no significant interaction between the membrane
treatment groups and time (p=0.7). While the ANOVA did indicate that there were differences
between the treatment groups, post-hoc analyses failed to identify differences below the 0.05
significance level, though the higher number of iNOS+ staining cells associated with the 500 μg
RK as compared to membranes with 100 μg RK approached statistical significance (p=0.056). It
is noted that it is not uncommon for the ANOVA to indicate that statistically significant
differences exist, but post-hoc analyses do not identify these differences. This occurs in part
because the ANOVA is more powerful than the post-hoc multiple comparison tests and when
difference between groups is not large, which may be the issue in this case. For the main factor
of time, post-hoc analyses indicated that the number of iNOS+ cells did not change significantly
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from week 1 to 2 for any of the groups (p=0.7) but did decrease significantly for all groups from
week 2 to 4 (p<0.001).
For the CD206+ staining (Figure 9C) analyses indicated that there was no significant
difference between the treatments (p=0.6), there was a significant difference over time (p<0.001)
and there was no significant interaction between the main factors (p=0.8). Post-hoc analyses
indicated that the number of CD206+ cells significantly increased from week 1 to 2 (p<0.001)
and then a significant decrease from week 2 to 4 (p=0.001).
Comparing the treatment groups, it was observed that there was a trend for there to be
fewer macrophages as indicated by CD68+ staining present in sections of the 500 μg RK loaded
membranes at all three time points as compared to the 100 μg RK and 0 RK loaded membranes
though not statistically significant at any time point. However, the macrophages in sections of
the 500μg RK loaded membranes tended to stain more strongly for the iNOS marker than the
other treatments groups at all three time points. While not statistically significant at any of the
time points, the higher staining for the iNOS marker of the 500 μg RK membrane group relative
to the 100 μg RK membrane group approached statistical significance (p=0.07) at week 2.
On the other hand, the proportion of pro-inflammatory iNOS+ cells tended to be lower
and the proportion of CD206+ cells tended to be greater for the 100 μg RK group as compared to
the others especially at the two-week time point, though statistical significance was not observed.
It is noted though that the lower iNOS+ staining of the 100 μg RK group as compared to the 500
μg RK group approached statistical significance (p=0.07) at the 2-week time point, and if outliers
are excluded statistical significance improved and P-value approached 0.06.
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Figure 9: The percentage of area positively stained by macrophage markers for different
treatment groups at different time points. CD68, iNOS and CD206 macrophage markers are
representative of total activated macrophages, M1 phenotypes, and M2 phenotypes, respectively.
Data represent mean ± standard deviation.
# indicates the statistical difference between week 2 and week 4 for specimens with No RK,
* indicates the statistical difference between week 2 and 4 for specimens with 100 μg RK,
@ indicates the statistical difference between week 1 and 4 for specimens with 500 μg RK,
** indicates the statistical difference between week 1 and week 2 for membranes with 100 μg RK,
## indicates the statistical difference between week 2 and week 4 for membranes with 100 μg RK.
All statistical significance indicates (P<0.05).

Figure 10 exhibits the area positively stained for M1 macrophages in comparison to M2
macrophage markers. At one week post implantation, the area stained for iNOS+ macrophages
are higher than that for CD206+ macrophages (more than 3 folds). However, at week 2, the area
stained positively for M2 macrophage marker has significantly increased in all treatment groups.
The M2/M1 ratio for 0 μg, 100 μg and 500 μg at week 2 was 0.76, 1.88 and 0.69, respectively.
This trend is followed at week 4 for both control and treatment groups, and M2/M1 ratio
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increased to 2.5, 6.66 and 1.72 in the lesion site of membrane-implanted animals with 0μg,
100μg and 500μg RK, respectively.

Figure 10: Comparison of the area positively stained for M1 macrophage marker (iNOS) and M2
macrophage marker (CD206) within different treatment groups in different time points. The M2to-M1 ratio is pointed on top of each bar in in red color.

Figure 11 shows the percent of CD206 positively stained area normalized to the total
(M1+M2) stained area. The data shows increasing trends in the M2/(M1+M2) ratio for all of the
RK dosages with increase in time points. However, for 100 μg RK the M2/(M1+M2) ratio was
higher than other groups at week 2, although that was not statistically significant. There was no
statistical difference for 100 μg Rk at different time points. Two-way analyses indicated that
there were no differences between the treatments (p=0.6), there was a significant difference over
time (p<0.001) and there was no significant interaction between the membrane treatment groups
and time (p=0.7). There was a significant increase in the M2/(M1+M2) ratio from week 1 to
week 2 (p=0.017) and from week 2 to week 4 (p=0.049).
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Figure 11: The percent area positively stained by CD206 normalized to total percent area
positively stained by iNOS and CD206, for different treatment groups at different time points.
Data represent mean ± standard deviation.
* indicates the statistical difference between week 1 and week 4 for specimens with 500μg RK,
$ indicates the statistical difference between week 2 and 4 for specimens with no RK,
# indicates the statistical difference between week 1 and week 4 for membranes with no RK,

Discussion
The aim of this study was to evaluate the effect of local delivery of RK into a rodent
calvarial bone defect site using electrospun chitosan membranes, to promote healing and bone
regeneration during guided bone regeneration therapy. It was hypothesized that the antiinflammatory characteristic of RK would enhance the healing process by stimulating the
transition of the macrophage phenotypes from pro-inflammatory (M1-macrophages) to prohealing (M2 macrophages).
The overall staining patterns observed reflected normal patterns of healing [57, 9]. There
was an overall increase in macrophages from week 1 to week 2 as indicated by the CD68+
staining, and then a decrease from week 2 to week 4. The presence of high numbers of iNOS
positive cells at the one-week time point is reflective of the initial inflammatory process in which
macrophages are removing dead/damaged tissues as well as any invading/contaminating
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microbes. However, at week 2, there was a trend for increased expression of CD206 marker for
the M2 phenotype. The increase in M2 macrophage phenotype marks the transition from the
initial inflammatory stage of healing to the next phase of healing involving tissue/extracellular
matrix elaboration to fill the defect. This increasing trend was more profound for 100 μg RK
treatment group (about 2 folds) than the other groups. Figure 11 also showed that M2/M1+M2
ratio increased more for 100 μg RK in comparison to other dosage at week 2, though the effect
was not statistically significant. By week 4, the total number of macrophages remaining as
indicated by CD68+ staining was low and of the cells remaining, staining was stronger for the
CD206 marker for the M2 pro-healing phenotype than the iNOS marker for the M1 proinflammatory phenotype. It has been reported that the success of biomaterial-mediated bone
formation is dependent on the efficient and timely switch from M1 to M2 phenotype during bone
healing while a prolonged M1 phase may result in fibrous encapsulation and failure of bone
regeneration [60]. The overall decrease in presence of macrophages, in particular the M1
phenotype, in treatment groups as well as the control by 4-week period is indicative of the
resolution of the inflammatory process, and that the membranes with and without RK did not
elicit a chronic inflammatory response. Prior studies examining ESCM also showed the
membranes to be biocompatible and to not elicit chronic inflammatory reactions that would
interfere with bone regeneration processes [54, 73].
The percent of sained area for macrophage markers suggested that while there was a trend
to be fewer macrophages present in sections of the 500 μg RK loaded membranes at all three
time points compared to the 100 μg RK and 0 RK loaded membranes. In addition, the majority
of macrophages present were more predominantly the M1 pro-inflammatory phenotype for the
500 μg RK loaded membranes than the other treatment groups. The reason that 500 μg RK
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loaded membranes showed fewer macrophages with higher proportion of M1 proinflammatory
phenotype compared to 100 μg RK loaded membranes may be due to both the release of RK
from the membranes and the effect of RK on macrophage cells. First, RK is reported to exhibit
dose dependent anti-inflammatory effects by suppressing iNOS and COX-2 pathways and the
release of NO and other pro-inflammatory cytokines/chemokines in LPS-stimulated murine
monocyte cells in vitro [11, 67]. Second, a prior study showed that RK release from hexanoic
modified membranes occurred over 11-14 days in vitro and that release profiles followed a burst
release pattern with the 500 μg RK loaded membranes releasing 5-6X higher levels of 100 μg
RK membranes over the first week of release [74]. The high release of RK by the 500 μg RK
loaded membranes may have inhibited the acute inflammation and the number of macrophages
in the defect by over suppressing pro-inflammatory cytokine/chemokine expressions leading to
lower levels of macrophage at early time points. This early inhibition may then have led to an
overall lower number of macrophages and a delay in progression the macrophages from the M1
to the M2 phenotype resulting in the increased proportion of M1 macrophages persisting in tissue
sections at the 2- and 4-week time points [75, 76]. It has been reported that eventual bone healing
is highly dependent on the initial inflammatory phase [77]. Also, the inhibition of initial
inflammatory the natural processes of acute inflammation has been shown to impair bone healing
[78]. These explanations support the results of an unpublished study in our lab that showed 500
μg RK membranes were not able to enhance bone formation and fill defects in the calvarial after
4 weeks compared to 100 μg RK.
Decreasing of iNOS expression at week 2 in 100 μg RK group could be due to the effect
of RK on inhibiting the activation of NF-ƘB pathway. This is in agreement with classical wound
healing response, and transition of macrophages from predominantly pro-inflammatory
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M1phenotypes present during initial inflammatory phase to anti-inflammatory M2 phenotype
present during later stages of wound healing [9, 79]. For the CD206+, there was no difference
between the 100 μg RK group and the others (p=0.6) but if outliers are excluded, the 100 μg RK
group exhibited greater CD206+ staining as compared to controls (p=0.047) but not to the 500 μg
RK group (p=0.7). This suggests that of the macrophages present, the majority were more
predominantly the M2 pro-healing phenotype for the 100 μg RK group as compared to the other
treatment groups). This may be due to the lower release of RK from the 100 μg RK loaded
membranes. The lower release levels appeared to have little effect on initial macrophage
response, and to have facilitated the transition of the macrophages from the M1 to the M2
phenotype. Preliminary in vitro studies using LPS-stimulated monocyte cells have shown that
RK in addition to reducing release of NO and other pro-inflammatory cytokines/chemokines can
increase the release of pro-healing cytokines/chemokines [67, 80]. This suggests that the lower
release levels of RK are not sufficient to inhibit the inflammatory response, but rather modulate
the response to favor increase in M2 macrophage phenotype that favor healing. This explanation
is further supported by unpublished results that showed significantly greater percent bone fill in
the calvarial defects treated with 100 μg RK membranes after 4 weeks as compared to 500 μg
RK or 0 μg RK membranes [70]. These results indicate that ESCM loaded with 100 μg RK may
have promising effects on accelerating the transition of macrophages from M1 pro-inflammatory
phenotypes to M2 pro-healing phenotypes. In future work, the use of a few doses of RK between
100 μg and 500 μg , and lower than100 μg per membrane is suggested because our results did
not show any benefit on promoting M1-M2 transition at higher doses of RK.
An in vitro study in our laboratory confirmed the potential of RK in promoting
macrophage transition to pro-healing M2 phenotypes when monocytes/macrophage-like cells

42

(RAW 264.7) were treated with different concentration of RK including 60, 120 and 240 μg
RK/ml medium [67]. It was indicated that RK at 120 μg/ml reduced proinflammatory cytokines
(TNFα, IL-1β) and increased anti-inflammatory/pro-healing cytokine (IL-10) compared to other
concentration of RKs [67]. This result is consistent with our in vivo finding that RK at
concentration of 100 μg per membrane is effective at accelerating M1 to M2 macrophage
transition.
Other studies have focused on manipulation of immunomodulatory properties of GBR
membranes to promote M1 to M2 transition and enhanced healing of GBR process. A study
conducted by Liang Yang et al, investigated the immunomodulatory properties of the small
intestinal submucosa (SIS) membrane modified by incorporation of strontium-substituted
nanohydroxyapatite coatings and/or IFN-γ to its surface, both in vitro and in vivo [10]. In vitro
results revealed that SIS/SrHA/IFN-γ membranes that mediated a sequential M1-M2
macrophages transition resulted in facilitated angiogenesis and osteogenesis. Moreover, in vivo
outcomes of subcutaneous implantation and calvarial defects confirmed that the above treatment
promoted vascularization and bone regeneration through immunomodulation. In both
subcutaneous and calvarial defect implantation the positively stained area for M2 increased at
longer time points (day 7 at subcutaneous and week 2 at calvarial defect models), while the
number of iNOS+ cells decreased. The increase in M2 numbers was correlated to enhanced bone
formation in the calvarial defects similar to the results of this work. This is in agreement with our
results that an enhanced bone formation for ESCM incorporating RK at 100 μg [70], which may
be correlated to the increased level of transition of macrophages to M2 phenotype.
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CHAPTER 4
CONCLUSION
In this study, we used immunohistochemical staining to characterize M1 and M2
macrophage phenotypes. iNOS and CD206 showed promising results for macrophage phenotype
staining. Our data demonstrated that RK plays a significant role in modulating inflammatory
response, and RK effects were dose dependent. Greater expression of M2 macrophage
phenotypes has been shown to have positive effects on osteogenesis and bone formation in GBR
process. Therefore, RK could be a promising alternative as a treatment for promoting healing in
dental defects without significant complications and costs associated with the use of growth
factors. Since results did not show any benefit on promoting M1-M2 transition at higher doses of
RK, examining a few doses of RK between 100 μg and 500 μg, and lower than100 μg per
membrane should be considered in future studies; it can provide more insight into the effective
doses of RK to be delivered through ESCM for an enhanced healing post GBR procedure.
Moreover, future preclinical animal studies can provide evidence of RK potentials for clinical
utility.
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CHAPTER 5
FUTURE WORKS AND RECOMMENDATIONS
Due to large standard deviation and variation in data, few significant statistical
differences were identified among the groups. This variation may be due in part to highly
technique sensitive nature of calvarial defect surgeries. Therefore, increasing the number of
animals for each group at different time points is suggested in future evaluations. In this study
we used immunohistochemical staining, using three serial sections, each for one of the
macrophage markers. This may be another reason for observed variation of outcomes. A double
or triple color immunofluorescent staining allows for identification of expression of different
macrophage markers in one section, providing a better indication of macrophage polarization on
that section. In future work, using the RK loaded membranes in an in vitro system and
performing PCR and ELISA for macrophage cytokine characterization and gene expression
might provide additional information on mechanisms for how RK modulates the response.
Since we observed more enhanced M1-to-M2 transition in response to membranes with
100μg RK, it is suggested that a few additional RK doses below and above 100 μg
RK/membrane to be studied as well. A positive control such as collagen membrane whose
biocompatibility has been investigated and confirmed in different studies can be added for
comparison with ESCMs. It is also suggested that staining for osteogenesis markers to be
performed to show the correlation between macrophage polarization and osteogenesis. In
addition, evaluation of macrophage polarization in more vascularized tissue can provide insight
into effects of RK on angiogenesis which could be further correlated with osteogenesis in bone
defect. Finally, testing in larger and more clinically relevant models such as rabbit, canine or
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goat might provide evidence of effectiveness for preparing toward approval through the FDA
process and translation to clinical practice.
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APPENDICES

Figure 12 shows percent of positively stained area plotted in different ways for
examining changes in macrophage populations in the histology sections.
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Figure 12: The percentage of area positively stained by macrophage markers for different
treatment groups at different time points. CD68, iNOS and CD206 macrophage markers are
representative of total activated macrophages, M1 phenotypes, and M2 phenotypes, respectively.
Data represent mean ± standard deviation.
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Figure 13 shows boxplots of the raw data demonstrating the variation and outliers in the
data of each marker for different treatments and different time points. Data represents
percentages of area positively stained for macrophage markers.

Figure 13: Boxplots of the percent of stained area for different treatment groups at different time
points
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Figure 14 shows how representative plots of CD68+ stained area and statistical
significances differ for different treatments, at different time points, when outliers are excluded
from data.

Figure 14: A. The percentage of area positively stained by CD68 for different treatment groups at
different time points (outliers included), B. The percentage of area positively stained by CD68
for different treatment groups at different time points (outliers excluded).
* indicates the statistical difference between week 1 and week 2 for specimens with 100μg RK,
# indicates the statistical difference between week 2 and 4 for specimens with 100μg RK,
** indicates the statistical difference between week 1 and week 2 for membranes with no RK,
## indicates the statistical difference between week 2 and week 4 for membranes with no RK.
All statistical significance indicates (P<0.05).
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Figure 15 shows how representative plots of iNOS+ stained area and statistical
significances differ for different treatments, at different time points, when outliers are excluded
from data.

Figure 15: A. The percentage of area positively stained by iNOS for different treatment groups at
different time points (outliers included), B. The percentage of area positively stained by iNOS
for different treatment groups at different time points (outliers excluded).
@ indicates the statistical difference between week 1 and week 4 for specimens with 500μg RK.
$ indicates the statistical difference between week 2 and 4 for specimens with 500μg RK.
# indicates the statistical difference between week 1 and week 4 for membranes with no RK, and
## indicates the statistical difference between week 2 and week 4 for membranes with no RK.
All statistical significance indicates (P<0.05).
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Figure 16 shows how representative plots of CD206+ stained area and statistical
significances differ for different treatments, at different time points, when outliers are excluded
from data.

Figure 16: A. The percentage of area positively stained by CD206 for different treatment groups
at different time points (outliers included), B.The percentage of area positively stained by CD206
for different treatment groups at different time points (outliers excluded).
* indicates the statistical difference between week 1 and week 2 for specimens with 100μg RK,
# indicates the statistical difference between week 2 and 4 for specimens with 100μg RK,
@ indicates the statistical difference between week 1 and week 2 for specimens with 500μg RK,
$ indicates the statistical difference between week 2 and 4 for specimens with 500μg RK. All
statistical significance indicates (P<0.05).
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Figure 17 shows boxplots of the raw data demonstrating the variation and outliers in the
data of each marker for different treatments and different time points. Data represents the
number of cells per unit area.

Figure 17: Box plots of the number of cells counted for all groups at different time points.
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Figure 18 shows how the number of macrophages changed a t the defect site in response
to different treatment over the 4-week time period. This figure was not used in the draft because
both the percentage area of positive staining and cell counts showed similar trend. It was chosen
to present the data just based on percentage of positively stained area to avoid redundancy.

61

(Cell/unit area)*10000000

CD68(PAN)
1400
1200
1000

0 µg RK

800

100 µg RK

600

500 µg RK

400
200
0
Week1

Week2

Week4

(Cell/unit area)*10000000

iNOS(M1)
1800
1600
1400
1200
1000
800
600
400
200
0

0 µg RK
100 µg RK
500 µg RK

(Cell/unit area)*10000000

Week1

Week2

Week4

CD206(M2)

1400
1200
1000

0 µg RK

800

100 µg RK

600

500 µg RK

400
200
0
Week1

Week2

Week4

Figure 18: The number of macrophages counted for different treatment groups at different time
points.
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Figure 19 provides plots of data comparing the number of M1 and M2 macrophage
phenotypes per unit area in the defect site at different time points during the healing process.
This figure was not used in the draft because both the percentage area of positive staining and
cell counts showed similar trend when comparing the quantity of M1 and M2 in each treatment
group at different time points. It was chosen to present the data just based on percentage of
positively stained area to avoid redundancy
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Figure 19: Comparison of the number of M1 and M2 for each group at different time points. The
M2-to-M1 ratio is pointed on top of each bar in red color.
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Figure 20 shows how the ratio of the number of M1 cell over total macrophages
(M1+M2) plotted in different ways for examining changes in macrophage populations in the
histology sections.
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Figure 20: The ratio of the number of M1 and M2 to total macrophages.
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